

Diana Prieto-Peña

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6494236/publications.pdf>

Version: 2024-02-01

53
papers

536
citations

758635

12
h-index

752256

20
g-index

55
all docs

55
docs citations

55
times ranked

528
citing authors

#	ARTICLE	IF	CITATIONS
1	Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 126-135.	1.6	66
2	Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 720-727.	1.6	63
3	Early large vessel systemic vasculitis in adults. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101424.	1.4	29
4	Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic. <i>RMD Open</i> , 2020, 6, e001297.	1.8	29
5	The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3.6-Year Prospective Study from a Referral Center of Interstitial Lung Disease and Lung Transplantation. <i>Journal of Clinical Medicine</i> , 2020, 9, 1606.	1.0	22
6	Current and emerging diagnosis tools and therapeutics for giant cell arteritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 593-605.	1.3	17
7	Treatment of polymyalgia rheumatica. <i>Biochemical Pharmacology</i> , 2019, 165, 221-229.	2.0	17
8	Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 105-114.	0.4	17
9	Unmet needs in the management of cardiovascular risk in inflammatory joint diseases. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 23-36.	1.3	16
10	Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 3070.	1.0	16
11	Endothelial Progenitor Cells as a Potential Biomarker in Interstitial Lung Disease Associated with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 4098.	1.0	16
12	Imaging Tests in the Early Diagnosis of Giant Cell Arteritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3704.	1.0	16
13	Treatment of giant cell arteritis. <i>Biochemical Pharmacology</i> , 2019, 165, 230-239.	2.0	15
14	Combined use of QRISK3 and SCORE as predictors of carotid plaques in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 2801-2807.	0.9	14
15	Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 387-394.	1.6	13
16	Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. <i>Polish Archives of Internal Medicine</i> , 2020, 131, 171-181.	0.3	13
17	The presence of both HLA-DRB1[*]04:01 and HLA-B[*]15:01 increases the susceptibility to cranial and extracranial giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 21-26.	0.4	13
18	Advances in the Treatment of Giant Cell Arteritis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1588.	1.0	11

#	ARTICLE	IF	CITATIONS
19	Moderate and High Disease Activity Predicts the Development of Carotid Plaque in Rheumatoid Arthritis Patients without Classic Cardiovascular Risk Factors: Six Years Follow-Up Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4975.	1.0	9
20	HLA association with the susceptibility to anti-synthetase syndrome. <i>Joint Bone Spine</i> , 2021, 88, 105115.	0.8	8
21	Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210932.	1.2	8
22	Cranial and extracranial giant cell arteritis share similar HLA-DRB1 association. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 897-901.	1.6	7
23	The Number of Traditional Cardiovascular Risk Factors Is Independently Correlated with Disease Activity in Patients with Psoriatic Arthritis. <i>Medicina (Lithuania)</i> , 2020, 56, 415.	0.8	7
24	Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110209.	1.2	7
25	A Review of the Dermatological Complications of Giant Cell Arteritis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2021, Volume 14, 303-312.	0.8	7
26	Drug therapies for polymyalgia rheumatica: a pharmacotherapeutic update. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1235-1244.	0.9	6
27	The role of biologics in the treatment of giant cell arteritis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 65-72.	1.4	6
28	Predicting the risk of relapse in polymyalgia rheumatica: novel insights. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 225-232.	1.3	5
29	BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis. <i>Scientific Reports</i> , 2021, 11, 11510.	1.6	5
30	Giant cell arteritis: more than a cranial disease. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 15-17.	0.4	5
31	Epidemiological and genetic features of anti-3-hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: Single-center experience and literature review. <i>European Journal of Internal Medicine</i> , 2022, 101, 86-92.	1.0	5
32	Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome. <i>Scientific Reports</i> , 2021, 11, 22574.	1.6	4
33	Long-term survival of lung transplantation for interstitial lung disease associated with connective tissue diseases: a study of 26 cases from a referral centre. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 615-620.	0.4	4
34	Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 105-114.	0.4	4
35	Utility of tocilizumab in autoimmune eye diseases. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 789-799.	1.4	4
36	Misperception of the Cardiovascular Risk in Patients with Rheumatoid Arthritis. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5954.	1.2	3

#	ARTICLE	IF	CITATIONS
37	Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2608.	1.0	3
38	Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice. <i>Journal of Rheumatology</i> , 2021, 48, 1552-1558.	1.0	3
39	Tocilizumab in giant cell arteritis: differences between the GACTA trial and a multicentre series of patients from the clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 112-119.	0.4	3
40	The presence of both HLA-DRB1*04:01 and HLA-B*15:01 increases the susceptibility to cranial and extracranial giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 21-26.	0.4	3
41	Angiogenic T Cells: Potential Biomarkers for the Early Diagnosis of Interstitial Lung Disease in Autoimmune Diseases?. <i>Biomedicines</i> , 2022, 10, 851.	1.4	3
42	SCORE2 Assessment in the Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis. <i>Diagnostics</i> , 2021, 11, 2363.	1.3	3
43	The role of PET/CT in the evaluation of patients with large-vessel vasculitis: useful for diagnosis but with potential limitations for follow-up. <i>Rheumatology</i> , 2022, 61, 4587-4589.	0.9	3
44	The Performance of Vascular Age in the Assessment of Cardiovascular Risk of Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 4065.	1.0	2
45	Diagnóstico de la arteritis de células gigantes. <i>Medicina Clínica</i> , 2021, 157, 285-287.	0.3	2
46	Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis. <i>Scientific Reports</i> , 2021, 11, 16163.	1.6	1
47	Molecular imaging in large vessel vasculitis has come to stay. <i>Annals of Translational Medicine</i> , 2018, 6, S2-S2.	0.7	1
48	Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	1
49	Severe microscopic polyangiitis limited to the skin. <i>Rheumatology</i> , 2021, , .	0.9	0
50	Cranial and extracranial giant cell arteritis do not have different HLA-DRB1 and HLA-B association in Caucasian individuals. <i>Arthritis Research and Therapy</i> , 2021, 23, 268.	1.6	0
51	Role of IRF5 in the pathogenesis of immunoglobulin-A vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 182-187.	0.4	0
52	Coexisting sarcoidosis and systemic lupus erythematosus: a case report and literature review. <i>Acta Reumatológica Portuguesa</i> , 2021, 46, 177-185.	0.2	0
53	Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0